Published in Circulation on July 04, 2006
Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart. Am J Physiol Heart Circ Physiol (2008) 1.95
Cytokines link Toll-like receptor 4 signaling to cardiac dysfunction after global myocardial ischemia. Ann Thorac Surg (2008) 1.91
Linking oxidative stress to inflammation: Toll-like receptors. Free Radic Biol Med (2010) 1.85
Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction. Clin Sci (Lond) (2008) 1.77
Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med (2012) 1.66
The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res (2011) 1.64
Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm Res (2008) 1.54
Differential toll-like receptor activation in lung ischemia reperfusion injury. J Thorac Cardiovasc Surg (2015) 1.44
Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol (2011) 1.36
Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm (2010) 1.35
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circ Res (2016) 1.27
Critical role of extracellular heat shock cognate protein 70 in the myocardial inflammatory response and cardiac dysfunction after global ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2008) 1.24
Myocardial TLR4 is a determinant of neutrophil infiltration after global myocardial ischemia: mediating KC and MCP-1 expression induced by extracellular HSC70. Am J Physiol Heart Circ Physiol (2009) 1.18
Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart. Transplantation (2009) 1.17
Novel critical role of Toll-like receptor 4 in lung ischemia-reperfusion injury and edema. Am J Physiol Lung Cell Mol Physiol (2009) 1.15
Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564). Invest Ophthalmol Vis Sci (2008) 1.12
Endogenous HMGB1 contributes to ischemia-reperfusion-induced myocardial apoptosis by potentiating the effect of TNF-α/JNK. Am J Physiol Heart Circ Physiol (2010) 1.10
Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine? Intensive Care Med (2010) 1.07
Interleukin-37 ameliorates myocardial ischaemia/reperfusion injury in mice. Clin Exp Immunol (2014) 1.04
Toll-like receptors: new players in myocardial ischemia/reperfusion injury. Antioxid Redox Signal (2011) 1.04
Toll-like receptors and myocardial inflammation. Int J Inflam (2011) 1.03
Role of extracellular RNA and TLR3-Trif signaling in myocardial ischemia-reperfusion injury. J Am Heart Assoc (2014) 1.01
The multiple facets of toll-like receptors in transplantation biology. Transplantation (2008) 0.99
Toll-like receptor 4 signaling in dysfunction of cardiac microvascular endothelial cells under hypoxia/reoxygenation. Inflamm Res (2010) 0.98
Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation. J Inflamm (Lond) (2010) 0.97
Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. Am J Physiol Heart Circ Physiol (2010) 0.97
The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease. Cardiol Res Pract (2012) 0.95
Toll-like receptor-4 mediates intestinal barrier breakdown after thermal injury. Surg Infect (Larchmt) (2010) 0.95
Alveolar macrophages and Toll-like receptor 4 mediate ventilated lung ischemia reperfusion injury in mice. Anesthesiology (2012) 0.95
Expression of toll-like receptor 4 contributes to corneal inflammation in experimental dry eye disease. Invest Ophthalmol Vis Sci (2012) 0.94
New insights into insulin: The anti-inflammatory effect and its clinical relevance. World J Diabetes (2014) 0.94
Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases. Cardiovasc Ther (2009) 0.92
The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation. Mediators Inflamm (2016) 0.92
CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion injury: involving activation of PI3K/Akt signaling. Biochim Biophys Acta (2012) 0.90
Ischemia-reperfusion lung injury is attenuated in MyD88-deficient mice. PLoS One (2013) 0.89
Toll-like receptors in ischaemia and its potential role in the pathophysiology of muscle damage in critical limb ischaemia. Cardiol Res Pract (2012) 0.89
The toll-like receptor 9 agonist, CpG-oligodeoxynucleotide 1826, ameliorates cardiac dysfunction after trauma-hemorrhage. Shock (2012) 0.89
Therapeutic targeting of innate immunity in the failing heart. J Mol Cell Cardiol (2010) 0.89
Resveratrol, a polyphenol phytoalexin, protects cardiomyocytes against anoxia/reoxygenation injury via the TLR4/NF-κB signaling pathway. Int J Mol Med (2012) 0.88
Innate immunity in the adult mammalian heart: for whom the cell tolls. Trans Am Clin Climatol Assoc (2010) 0.87
Upregulation of TLR2/4 expression in mononuclear cells in postoperative systemic inflammatory response syndrome after liver transplantation. Mediators Inflamm (2010) 0.86
Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation. Int J Endocrinol (2014) 0.85
Toll-like receptors and myocardial ischemia/reperfusion, inflammation, and injury. Curr Cardiol Rev (2009) 0.85
Toll-like Receptors in the Vascular System: Sensing the Dangers Within. Pharmacol Rev (2016) 0.84
The emerging role of Toll-like receptor 4 in myocardial inflammation. Cell Death Dis (2016) 0.84
Acute kidney injury: a conspiracy of Toll-like receptor 4 on endothelia, leukocytes, and tubules. Pediatr Nephrol (2011) 0.83
Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertension. J Neuroinflammation (2015) 0.83
Retracted Pterostilbene attenuates inflammation in rat heart subjected to ischemia-reperfusion: role of TLR4/NF-κB signaling pathway. Int J Clin Exp Med (2015) 0.82
Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy. J Biol Chem (2012) 0.82
TLR accessory molecule RP105 (CD180) is involved in post-interventional vascular remodeling and soluble RP105 modulates neointima formation. PLoS One (2013) 0.80
Graft rejection - endogenous or allogeneic? Immunology (2012) 0.80
TLR4/NF-κB-responsive microRNAs and their potential target genes: a mouse model of skeletal muscle ischemia-reperfusion injury. Biomed Res Int (2015) 0.79
Cardioprotective effect of carvedilol: inhibition of apoptosis in H9c2 cardiomyocytes via the TLR4/NF-κB pathway following ischemia/reperfusion injury. Exp Ther Med (2014) 0.78
Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14(+) Monocytes. J Immunol (2017) 0.77
Genome-wide association study of new-onset atrial fibrillation after coronary artery bypass grafting surgery. Am Heart J (2015) 0.77
Cross talk of the first-line defense TLRs with PI3K/Akt pathway, in preconditioning therapeutic approach. Mol Cell Ther (2015) 0.76
Toll-like receptor 4 plays a central role in cardiac dysfunction during trauma hemorrhage shock. Shock (2014) 0.76
Genomics in cardiovascular diseases: analysis of the importance of the toll-like receptor signaling pathway. Int J Gen Med (2012) 0.75
Attenuated recovery of contractile function in aging hearts following global ischemia/reperfusion: Role of extracellular HSP27 and TLR4. Mol Med (2016) 0.75
Stanniocalcin-1 attenuates ischemic cardiac injury and response of differentiating monocytes/macrophages to inflammatory stimuli. Transl Res (2016) 0.75
Toll-like receptor 4 mediates the inflammatory responses and matrix protein remodeling in remote non-ischemic myocardium in a mouse model of myocardial ischemia and reperfusion. PLoS One (2015) 0.75
BET protein inhibition mitigates acute myocardial infarction damage in rats via the TLR4/TRAF6/NF-κB pathway. Exp Ther Med (2015) 0.75
Tenascin C upregulates interleukin-6 expression in human cardiac myofibroblasts via toll-like receptor 4. World J Cardiol (2016) 0.75
Sequence variation in PPP1R13L results in a novel form of cardio-cutaneous syndrome. EMBO Mol Med (2017) 0.75
A novel 72-kDa leukocyte-derived osteoglycin enhances the activation of toll-like receptor 4 and exacerbates cardiac inflammation during viral myocarditis. Cell Mol Life Sci (2016) 0.75
Innate immune receptors in heart failure: Side effect or potential therapeutic target? World J Cardiol (2014) 0.75
Plasma Monocyte Chemotactic Protein-1 Is Associated With Acute Kidney Injury and Death After Cardiac Operations. Ann Thorac Surg (2017) 0.75
Toll-like Receptor 4 Deficiency Reduces Oxidative Stress and Macrophage Mediated Inflammation in Hypertensive Kidney. Sci Rep (2017) 0.75
Inhibition of Toll-Like Receptor Signaling as a Promising Therapy for Inflammatory Diseases: A Journey from Molecular to Nano Therapeutics. Front Physiol (2017) 0.75
Exosomes as agents of change in the cardiovascular system. J Mol Cell Cardiol (2017) 0.75
Factors associated with primary graft failure after heart transplantation. Transplantation (2010) 2.38
Development of a novel echocardiography ramp test for speed optimization and diagnosis of device thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp study. J Am Coll Cardiol (2012) 2.33
Effects of continuous-flow versus pulsatile-flow left ventricular assist devices on myocardial unloading and remodeling. Circ Heart Fail (2011) 2.19
Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation (2012) 2.17
Modified Bentall operation with a novel biologic valved conduit. Ann Thorac Surg (2010) 2.03
Toll-like receptor 4 mediates lung ischemia-reperfusion injury. Ann Thorac Surg (2006) 1.97
Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation (2007) 1.97
Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: correction after ventricular assist device implantation. Circ Heart Fail (2012) 1.79
Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg (2004) 1.71
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg (2010) 1.60
Use of carotid-subclavian arterial bypass and thoracic endovascular aortic repair to minimize cerebral ischemia in total aortic arch reconstruction. J Thorac Cardiovasc Surg (2010) 1.54
Preoperative assessment of high-risk candidates to predict survival after heart transplantation. Circ Heart Fail (2013) 1.53
Long-term outcome for the surgical treatment of infective endocarditis with a focus on intravenous drug users. Ann Thorac Surg (2011) 1.49
Contemporary Outcomes of Venoarterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock at a Large Tertiary Care Center. ASAIO J (2015) 1.48
Tenascin-C synthesized in both donor grafts and recipients accelerates artery graft stenosis. Cardiovasc Res (2007) 1.48
Molecular diagnosis of prosthetic valve endocarditis with aorto-right atrial fistula. Int J Cardiol (2008) 1.46
Dynamics of bone turnover markers in patients with heart failure and following haemodynamic improvement through ventricular assist device implantation. Eur J Heart Fail (2012) 1.43
Molecular diagnosis of nonaneurysmal infectious aortitis. J Vasc Surg (2010) 1.42
Impact of aortic annular size on rate of reoperation for left ventricular outflow tract obstruction after repair of interrupted aortic arch and ventricular septal defect. Ann Thorac Surg (2010) 1.42
Method of cell transplantation promoting the organization of intraarterial thrombus. Circulation (2005) 1.40
Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg (2006) 1.39
Sustained supervised practice on a coronary anastomosis simulator increases medical student interest in surgery, unsupervised practice does not. Ann Thorac Surg (2013) 1.39
POINT: Are surgeons ethically obligated to treat Medicare patients despite substantial reductions in reimbursement? J Thorac Cardiovasc Surg (2013) 1.37
Acute valvular regurgitation. Circulation (2009) 1.37
Myocardial infarction following coronary artery bypass graft surgery increases healthcare resource utilization. Crit Care Med (2007) 1.35
Prevalence of de novo aortic insufficiency during long-term support with left ventricular assist devices. J Heart Lung Transplant (2010) 1.28
Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol (2009) 1.25
High lung allocation score is associated with increased morbidity and mortality following transplantation. Chest (2009) 1.22
Early activation of the alveolar macrophage is critical to the development of lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2003) 1.22
The role of proinflammatory cytokines in lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2003) 1.21
A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest (2007) 1.19
Impella LP 2.5 for left ventricular unloading during venoarterial extracorporeal membrane oxygenation support. J Card Surg (2011) 1.16
Subclavian artery cannulation for venoarterial extracorporeal membrane oxygenation. ASAIO J (2012) 1.16
Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg (2002) 1.16
Hepatic dysfunction and survival after orthotopic heart transplantation: application of the MELD scoring system for outcome prediction. J Heart Lung Transplant (2012) 1.13
Successful repair of an aortoesophageal fistula with aneurysm from esophageal diverticulum. Ann Thorac Surg (2002) 1.12
Regulation of chemokine expression by cyclosporine A in alveolar macrophages exposed to hypoxia and reoxygenation. Ann Thorac Surg (2002) 1.12
Who is the high-risk recipient? Predicting mortality after heart transplant using pretransplant donor and recipient risk factors. Ann Thorac Surg (2011) 1.09
Simple preoperative management for cold agglutinins before cardiac surgery. J Thorac Cardiovasc Surg (2010) 1.08
Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost (2010) 1.07
Ventricular arrhythmias and implantable cardioverter-defibrillator therapy in patients with continuous-flow left ventricular assist devices: need for primary prevention? J Am Coll Cardiol (2013) 1.06
Sacral resection and reconstruction for tumors and tumor-like conditions. Orthopedics (2005) 1.05
Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation (2004) 1.05
Relation of preoperative serum albumin levels to survival in patients undergoing left ventricular assist device implantation. Am J Cardiol (2013) 1.04
Liver dysfunction as a predictor of outcomes in patients with advanced heart failure requiring ventricular assist device support: Use of the Model of End-stage Liver Disease (MELD) and MELD eXcluding INR (MELD-XI) scoring system. J Heart Lung Transplant (2012) 1.02
Preoperative serum albumin levels predict 1-year postoperative survival of patients undergoing heart transplantation. Circ Heart Fail (2013) 1.02
Critical role of reactive nitrogen species in lung ischemia-reperfusion injury. J Heart Lung Transplant (2003) 1.00
Safe transport of critically ill adult patients on extracorporeal membrane oxygenation support to a regional extracorporeal membrane oxygenation center. ASAIO J (2011) 1.00
Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol (2010) 1.00
Usefulness of two-dimensional echocardiographic parameters of the left side of the heart to predict right ventricular failure after left ventricular assist device implantation. Am J Cardiol (2011) 0.97
Pre-operative and post-operative risk factors associated with neurologic complications in patients with advanced heart failure supported by a left ventricular assist device. J Heart Lung Transplant (2011) 0.96
Laparoscopic surgery in children with congenital heart disease. J Pediatr Surg (2012) 0.96
Crosstalk between thrombosis and inflammation in lung reperfusion injury. Ann Thorac Surg (2006) 0.96
Long-term results of radiofrequency ablation in colorectal lung metastases: single center experience. Oncol Rep (2009) 0.96
HSP70.1 and -70.3 are required for late-phase protection induced by ischemic preconditioning of mouse hearts. Am J Physiol Heart Circ Physiol (2003) 0.96
Consensus statement: Defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surg Forum (2008) 0.96
A novel protocol of retrograde cerebral perfusion with intermittent pressure augmentation for brain protection. J Thorac Cardiovasc Surg (2005) 0.96
Aortic valve procedures at the time of ventricular assist device placement. Ann Thorac Surg (2011) 0.94
Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury. Ann Thorac Surg (2003) 0.94
Evaluation of web-based learning tools: lessons learned from the thoracic surgery directors association curriculum project three-year experience. Ann Thorac Surg (2005) 0.93
Del Nido Cardioplegia can be safely administered in high-risk coronary artery bypass grafting surgery after acute myocardial infarction: a propensity matched comparison. J Cardiothorac Surg (2014) 0.93
Prevalence, significance, and management of aortic insufficiency in continuous flow left ventricular assist device recipients. Circ Heart Fail (2014) 0.93
Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats. J Thorac Cardiovasc Surg (2004) 0.93
In vivo plaque composition and morphology in coronary artery lesions in adolescents and young adults long after Kawasaki disease: a virtual histology-intravascular ultrasound study. Circulation (2009) 0.93
Assessment of safety of lactobacillus strains based on resistance to host innate defense mechanisms. Clin Diagn Lab Immunol (2003) 0.92
Novel broad-spectrum chemokine inhibitor protects against lung ischemia-reperfusion injury. J Heart Lung Transplant (2004) 0.92
Validity and reliability of a novel slow cuff-deflation system for noninvasive blood pressure monitoring in patients with continuous-flow left ventricular assist device. Circ Heart Fail (2013) 0.92
A decade of pediatric mechanical circulatory support before and after cardiac transplantation. J Thorac Cardiovasc Surg (2011) 0.92
Comparison of cardiothoracic training curricula: integrated six-year versus traditional programs. Ann Thorac Surg (2013) 0.92
Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis. Eur J Heart Fail (2012) 0.91
Impact of long term left ventricular assist device therapy on donor allocation in cardiac transplantation. J Heart Lung Transplant (2013) 0.91
Consensus statement: minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surg Forum (2010) 0.91
Predictive value of the Seattle Heart Failure Model in patients undergoing left ventricular assist device placement. J Heart Lung Transplant (2010) 0.90
Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res (2002) 0.90
Incidence and Implications of Left Ventricular Distention During Venoarterial Extracorporeal Membrane Oxygenation Support. ASAIO J (2017) 0.89
Massive hemoptysis from pulmonary artery pseudoaneurysm caused by lung radiofrequency ablation: successful treatment by coil embolization. Cardiovasc Intervent Radiol (2009) 0.88
Human immunodeficiency virus infection and left ventricular assist devices: a case series. J Heart Lung Transplant (2011) 0.88
Right atrial lesions do not improve the efficacy of a complete left atrial lesion set in the surgical treatment of atrial fibrillation, but they do increase procedural morbidity. J Thorac Cardiovasc Surg (2013) 0.88
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice. Cardiovasc Res (2005) 0.88
Mitral valve repair at the time of continuous-flow left ventricular assist device implantation confers meaningful decrement in pulmonary vascular resistance. ASAIO J (2013) 0.88